113 related articles for article (PubMed ID: 2743591)
21. Dopaminergic modulation of aldosterone secretion: effect of sodium balance and postural changes.
García-Robles R; Ruilope L; Mancheño E; Hurtado A; Alcázar JM; Varela C; de la Calle H; Rodicio JL; Sancho J
Rev Esp Fisiol; 1984 Mar; 40(1):63-8. PubMed ID: 6087430
[TBL] [Abstract][Full Text] [Related]
22. Escape from the sodium-retaining effects of mineralocorticoids: is there a role for dopamine?
Coruzzi P
J Clin Endocrinol Metab; 1994 Feb; 78(2):455-8. PubMed ID: 8106635
[TBL] [Abstract][Full Text] [Related]
23. Sodium depletion increases platelet and plasma catecholamines in hypertensive men.
Kjeldsen SE; Westheim A; Lande K; Gjesdal K; Leren P; Enger E; Eide IK
Hypertension; 1988 May; 11(5):477-82. PubMed ID: 3366481
[TBL] [Abstract][Full Text] [Related]
24. Dopamine D3 receptor in peripheral mononuclear cells of essential hypertensives.
Ricci A; Bronzetti E; Mulatero P; Schena M; Veglio F; Amenta F
Hypertension; 1997 Dec; 30(6):1566-71. PubMed ID: 9403584
[TBL] [Abstract][Full Text] [Related]
25. Effect of metoclopramide on plasma catecholamine release in essential hypertension.
Kuchel O; Buu NT; Hamet P; Larochelle P
Clin Pharmacol Ther; 1985 Apr; 37(4):372-5. PubMed ID: 3978997
[TBL] [Abstract][Full Text] [Related]
26. Increased plasma free dopamine after treatment with atenolol and oxprenolol in essential hypertension.
Kjeldsen SE; Eide I; Aakesson I; Amundsen R; Eriksen IL; Leren P
Acta Med Scand; 1983; 214(5):367-71. PubMed ID: 6660046
[TBL] [Abstract][Full Text] [Related]
27. [Relation between dopamine secretion and saltsensitivity in essential hypertension].
Haruyama K; Shigetomi S; Yamazaki M; Hashimoto S; Yaginuma K; Fukuchi S
Nihon Naibunpi Gakkai Zasshi; 1983 Oct; 59(10):1658-66. PubMed ID: 6363145
[TBL] [Abstract][Full Text] [Related]
28. [Dopaminergic modulation of salt sensitivity in essential hypertension].
Shikuma R; Kambara S; Yoshimura M; Takashina R; Yamasaki H; Takeda K; Takahashi H; Ijichi H
Nihon Jinzo Gakkai Shi; 1984 Apr; 26(4):417-23. PubMed ID: 6381832
[No Abstract] [Full Text] [Related]
29. Dopamine-induced antihypertensive effects and plasma insulin rise are blocked by metoclopramide in labetalol-treated patients.
Martin G; Forte P; Luchsinger A; Mendoza F; Urbina-Quintana A; Hernandez Pieretti O; Romero E; Velasco M
J Clin Pharmacol; 1994 Jan; 34(1):91-4. PubMed ID: 8132857
[TBL] [Abstract][Full Text] [Related]
30. Dopaminergic blockade of the renin-angiotensin-aldosterone system: effect of high and low sodium intakes.
Gordon MB; Moore TJ; Dluhy RG; Williams GH
Clin Endocrinol (Oxf); 1983 Oct; 19(4):415-25. PubMed ID: 6354522
[TBL] [Abstract][Full Text] [Related]
31. [The role of the renal dopaminergic and the prostaglandin systems in renal uric acid metabolism in patients with essential hypertension].
Satoh N; Kikuchi K; Hasegawa T; Komura H; Suzuki S; Ohtomo T; Takada T; Nanba M; Marusaki S; Iimura O
Nihon Naibunpi Gakkai Zasshi; 1991 Nov; 67(11):1271-81. PubMed ID: 1761141
[TBL] [Abstract][Full Text] [Related]
32. Free and conjugated catecholamines in plasma and red blood cells of normotensive and hypertensive patients.
de Champlain J; Bouvier M; Cléroux J; Farley L
Clin Exp Hypertens A; 1984; 6(1-2):523-37. PubMed ID: 6697563
[TBL] [Abstract][Full Text] [Related]
33. Enhanced response of plasma aldosterone to metoclopramide in essential hypertension.
Stern N; Sowers JR; Tuck M; Eshkol A; Lunenfeld B; Rosenthal T
J Hypertens; 1984 Apr; 2(2):209-14. PubMed ID: 6398336
[TBL] [Abstract][Full Text] [Related]
34. Effect of dopamine and dopamine-antagonist infusion on blood platelet count, size and release reaction in hypertensive and normotensive subjects.
Lande K; Os I; Kjeldsen SE; Westheim A; Hjermann I; Eide I; Gjesdal K
Scand J Clin Lab Invest; 1989 Jun; 49(4):307-15. PubMed ID: 2525805
[TBL] [Abstract][Full Text] [Related]
35. Influence of sodium homeostasis and circadian rhythm on dopaminergic modulation of 18-hydroxycorticosterone secretion in man.
Sowers JR; Stern N
J Clin Endocrinol Metab; 1982 Dec; 55(6):1046-51. PubMed ID: 7130335
[TBL] [Abstract][Full Text] [Related]
36. Total plasma dopamine/norepinephrine ratio in catecholamine-secreting tumors. Its relation to hypertension.
Puyo A; Levin G; Armando I; Barontini M
Hypertension; 1988 Feb; 11(2 Pt 2):I202-6. PubMed ID: 3346058
[TBL] [Abstract][Full Text] [Related]
37. Metoclopramide, domperidone and dopamine in man: actions and interactions.
MacDonald TM
Eur J Clin Pharmacol; 1991; 40(3):225-30. PubMed ID: 2060557
[TBL] [Abstract][Full Text] [Related]
38. Selectivity of metoclopramide for endocrine versus renal effects of dopamine in normal humans.
Blumberg AL; Dubb JW; Allison NL; Aldins Z; Ramey K; Stote RM
J Cardiovasc Pharmacol; 1988 Feb; 11(2):181-6. PubMed ID: 2452312
[TBL] [Abstract][Full Text] [Related]
39. Dopamine blockade abolishes the exaggerated natriuresis of essential hypertension.
Coruzzi P; Musiari L; Biggi A; Ravanetti C; Novarini A
J Hypertens; 1987 Oct; 5(5):587-91. PubMed ID: 3323313
[TBL] [Abstract][Full Text] [Related]
40. Effects of dopaminergic antagonists on dopamine-induced cardiovascular and insulin secretion actions in hypertensive patients.
Forte P; Martin G; Luchsinger A; Hernandez O; Romero E; Velasco M
Int J Clin Pharmacol Ther Toxicol; 1993 Aug; 31(8):404-6. PubMed ID: 8225687
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
